You are here

  • Home
  • Archive
  • Volume 2, Issue 1
  • Serum concentrations of endothelial cell adhesion molecules and their shedding enzymes and early onset sepsis in newborns in Suriname

Article Text

Article menu

Download PDFPDF

XML
Infectious Diseases
Original article
Serum concentrations of endothelial cell adhesion molecules and their shedding enzymes and early onset sepsis in newborns in Suriname
  1. Rens Zonneveld1,2,
  2. Rianne M Jongman1,3,4,
  3. Amadu Juliana2,
  4. Grietje Molema1,
  5. Matijs van Meurs1,3,
  6. Frans B Plötz5
  1. 1 Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  2. 2 Academic Pediatric Center Suriname, Academic Hospital Paramaribo, Paramaribo, Suriname
  3. 3 Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  4. 4 Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  5. 5 Department of Pediatrics, Tergooi Hospitals, Blaricum, The Netherlands
  1. Correspondence to Dr Rens Zonneveld; rens.zonneveld{at}gmail.com

Abstract

Background Early onset sepsis (EOS) is defined as onset of sepsis within 72 hours after birth. Leucocyte-endothelial interactions play a pivotal part in EOS pathophysiology. Endothelial cell adhesion molecules (CAMs) orchestrate these interactions and their soluble isoforms (sCAMs) are released into the vasculature by enzymes called sheddases.

Purpose This study was undertaken to explore further the pathophysiology of EOS and to investigate the potential of sCAM and their sheddases as potential biomarkers for EOS.

Methods Stored serum aliquots were used from 71 Surinamese newborns suspected of EOS and 20 healthy newborns from an earlier study. Serum had been collected within 72 hours after birth and six (8.6%) newborns had a positive blood culture with gram-negative pathogens. Concentrations of sCAMs sP-selectin, sE-selectin, soluble vascular cell adhesion molecule-1 , intercellular adhesion molecule-1 and platelet and endothelial cell adhesion molecule-1, sheddases matrix metalloproteinase-9 (MMP-9) and neutrophil elastase (NE) and sheddase antagonist tissue-inhibitor of metalloproteinases-1 (TIMP-1) were measured simultaneously with Luminex and ELISA.

Results MMP-9 and TIMP-1 levels were measured in serum of n=91 newborns and sCAMs and NE levels in serum of n=80 newborns, respectively. We found no differences in median concentrations of sCAMs, MMP-9 and TIMP-1 or NE between blood culture positive EOS, blood culture negative EOS and control groups at start of antibiotic treatment.

Conclusions Our data indicate that serum concentrations of sCAMs and their sheddases have no clinical utility as biomarkers for EOS.

Trial registration number NCT02486783. Results

  • newborns
  • early onset sepsis
  • adhesion molecules
  • shedding
  • Suriname

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjpo-2018-000312

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RZ, MvM, GM and FBP conceived and designed the study. RZ and AJ collected clinical data and collected the samples. RZ, RMJ and MvM prepared the samples and performed the sample analysis. RZ and MvM analysed the final database. RZ, MvM, GM and FBP drafted the manuscript. All authors coauthored and approved the final manuscript.

    • Funding The Thrasher Research Fund (TRF13064) and Tergooi Hospitals, Blaricum, The Netherlands.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Surinamese Medical Ethical Board.

    • Provenance and peer review Not commissioned; externally peer reviewed.